Research Analysts Issue Forecasts for Genmab A/S Q3 Earnings

Genmab A/S (NASDAQ:GMAB) – William Blair issued their Q3 2025 earnings per share (EPS) estimates for Genmab A/S in a research note issued on Thursday, February 13th. William Blair analyst M. Phipps anticipates that the company will earn $0.46 per share for the quarter. The consensus estimate for Genmab A/S’s current full-year earnings is $1.25 per share. William Blair also issued estimates for Genmab A/S’s Q4 2025 earnings at $0.44 EPS and FY2028 earnings at $4.02 EPS.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%.

GMAB has been the subject of several other research reports. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research note on Thursday. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus price target of $42.17.

Genmab A/S Stock Performance

GMAB stock opened at $21.30 on Monday. Genmab A/S has a one year low of $18.64 and a one year high of $31.88. The firm has a market cap of $14.10 billion, a price-to-earnings ratio of 20.68, a PEG ratio of 0.54 and a beta of 0.96. The firm has a 50-day simple moving average of $20.65 and a two-hundred day simple moving average of $23.11.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC increased its holdings in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after purchasing an additional 939 shares in the last quarter. Lindbrook Capital LLC grew its position in Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after buying an additional 950 shares during the period. GAMMA Investing LLC increased its holdings in Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after buying an additional 1,051 shares in the last quarter. Barclays PLC raised its position in shares of Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after acquiring an additional 2,285 shares during the period. Finally, Cromwell Holdings LLC boosted its stake in shares of Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after acquiring an additional 2,496 shares in the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.